BioCardia wins FDA backing for single-trial PMA path for CardiAMP
BioCardia has received formal written confirmation from the US Food and Drug Administration that its ongoing CardiAMP Heart Failure II trial may serve as the basis for a Premarket Approval (PMA) application for the CardiAMP Cell Therapy System in ischaemic heart failure with reduced ejection fraction (HFrEF). The minutes, issued by the FDA's Centre for Biologics Evaluation and Research (CBER) following a Q-Sub meeting, represent a meaningful concession from an agency that has historically preferred to see two well-designed pivotal trials before approving therapies targeting large patient populations.
The PMA pathway is the most stringent marketing authorisation route available for high-risk medical devices and biologics in the United States. For BioCardia, the confirmation is significant because HFrEF is a broad indication — the company estimates more than one million US patients could be eligible for the therapy — and regulators have typically been conservative about approving novel interventional approaches in this population on the basis of a single study.
The CardiAMP programme
CardiAMP Cell Therapy is an autologous procedure that harvests a patient's own bone marrow cells and delivers them to the heart via a catheter-based system. The intended mechanism involves increasing capillary density and reducing myocardial fibrosis to address microvascular dysfunction. The therapy carries FDA Breakthrough Device designation, which provides for more frequent agency interaction and may expedite review timelines. Centres for Medicare and Medicaid Services (CMS) has authorised reimbursement during the clinical trials, which the company describes as evidence that the FDA has already determined the therapy to be safe in an investigational context.
Separately, Japan's Pharmaceutical and Medical Device Agency (PMDA) has signalled that data from three completed clinical studies likely provides sufficient evidence to support a regulatory submission in that market. BioCardia has listed a Japan PMDA submission as a Q4 2026 milestone, alongside publication of the CardiAMP HF manuscript.
Chief executive Peter Altman said the FDA's recognition of the completed CardiAMP HF data as the first of two trials — implying the ongoing HF II study may stand alone — reflected the "great need" among patients with ischaemic HFrEF for new therapeutic options.
Market context and competitive landscape
The cell therapy space for cardiac indications has a long and chequered history. Multiple earlier autologous cell programmes, including mesenchymal stem cell and CD34+ approaches from other developers, produced inconsistent Phase 2 results and failed to progress to approval, dampening investor appetite in the sector through much of the 2010s. BioCardia's Breakthrough designation and the CMS reimbursement precedent are intended to address some of that scepticism, but the field has yet to yield an approved cellular cardiac product in the US.
The broader HFrEF therapeutic landscape is crowded with approved pharmacological agents — SGLT2 inhibitors, sacubitril/valsartan, and guideline-directed device therapies — meaning any novel modality will need to demonstrate additive benefit in patients already receiving optimised background therapy. How the CardiAMP HF II trial is designed relative to those background therapies will be closely scrutinised when full data are published. The forthcoming manuscript from the first CardiAMP HF trial is therefore a near-term read-across event that could shape both investor and regulatory sentiment ahead of any PMA submission.
BioCardia has not disclosed enrolment numbers, interim data, or a projected PMA submission timeline, leaving the market to judge the news primarily on the procedural FDA confirmation rather than clinical substance.